- Home
- OABI vs TRVI Comparison
OABI vs TRVI Comparison
Compare OABI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- TRVI
- Stock Information
- Founded
- OABI 2012
- TRVI 2011
- Country
- OABI United States
- TRVI United States
- Employees
- OABI N/A
- TRVI N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- TRVI Health Care
- Exchange
- OABI Nasdaq
- TRVI Nasdaq
- Market Cap
- OABI 389.7M
- TRVI 363.7M
- IPO Year
- OABI N/A
- TRVI 2019
- Fundamental
- Price
- OABI $3.65
- TRVI $4.60
- Analyst Decision
- OABI Strong Buy
- TRVI Strong Buy
- Analyst Count
- OABI 4
- TRVI 8
- Target Price
- OABI $9.00
- TRVI $9.31
- AVG Volume (30 Days)
- OABI 569.4K
- TRVI 739.7K
- Earning Date
- OABI 03-19-2025
- TRVI 03-19-2025
- Dividend Yield
- OABI N/A
- TRVI N/A
- EPS Growth
- OABI N/A
- TRVI N/A
- EPS
- OABI N/A
- TRVI N/A
- Revenue
- OABI $20,409,000.00
- TRVI N/A
- Revenue This Year
- OABI N/A
- TRVI N/A
- Revenue Next Year
- OABI $78.61
- TRVI N/A
- P/E Ratio
- OABI N/A
- TRVI N/A
- Revenue Growth
- OABI N/A
- TRVI N/A
- 52 Week Low
- OABI $3.10
- TRVI $2.30
- 52 Week High
- OABI $6.55
- TRVI $5.05
- Technical
- Relative Strength Index (RSI)
- OABI 53.96
- TRVI 62.80
- Support Level
- OABI $3.61
- TRVI $3.93
- Resistance Level
- OABI $4.02
- TRVI $4.14
- Average True Range (ATR)
- OABI 0.18
- TRVI 0.29
- MACD
- OABI 0.04
- TRVI 0.06
- Stochastic Oscillator
- OABI 58.89
- TRVI 64.82
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.